Bristol Myers Squibb Announces Positive SCOUT-HCM Trial Results for Camzyos in Adolescent oHCM Patients

Bristol Myers Squibb has announced positive topline results from the Phase 3 SCOUT-HCM trial evaluating Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The trial demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpoints, and the overall safety results were consistent with the established safety profile in adults. The results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM.